PE20110055A1 - Dronedarona para la prevencion de la fibrilacion auricular permanente - Google Patents

Dronedarona para la prevencion de la fibrilacion auricular permanente

Info

Publication number
PE20110055A1
PE20110055A1 PE2010001117A PE2010001117A PE20110055A1 PE 20110055 A1 PE20110055 A1 PE 20110055A1 PE 2010001117 A PE2010001117 A PE 2010001117A PE 2010001117 A PE2010001117 A PE 2010001117A PE 20110055 A1 PE20110055 A1 PE 20110055A1
Authority
PE
Peru
Prior art keywords
dronedarone
atrial fibrillation
prevention
permanent atrial
atrial
Prior art date
Application number
PE2010001117A
Other languages
English (en)
Inventor
Christophe Gaudin
Nacera Hamdani
Davide Radzik
Eickels Martin Van
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110055(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20110055A1 publication Critical patent/PE20110055A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)

Abstract

REFERIDA AL 2-n-BUTIL-3-[4-(3-DI-n-BUTILAMINOPROPOXI)BENZOIL]-5-METILSULFONAMIDOBENZOFURANO O DRONEDARONA, EL CUAL ES UN AGENTE BLOQUEANTE MULTICANAL SOBRE LOS CANALES DE CALCIO, POTASIO Y SODIO Y ES UTIL EN EL TRATAMIENTO DE PACIENTES CON HISTORIAL DE FIBRILACION AURICULAR O ALETEO AURICULAR
PE2010001117A 2008-06-10 2009-06-08 Dronedarona para la prevencion de la fibrilacion auricular permanente PE20110055A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6026308P 2008-06-10 2008-06-10
EP08290531A EP2133074A1 (en) 2008-06-10 2008-06-10 Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation

Publications (1)

Publication Number Publication Date
PE20110055A1 true PE20110055A1 (es) 2011-02-11

Family

ID=39731657

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010001117A PE20110055A1 (es) 2008-06-10 2009-06-08 Dronedarona para la prevencion de la fibrilacion auricular permanente

Country Status (24)

Country Link
US (1) US20110166220A1 (es)
EP (2) EP2133074A1 (es)
JP (1) JP2011522876A (es)
KR (1) KR20110026422A (es)
CN (1) CN102056603A (es)
AR (1) AR072069A1 (es)
AU (1) AU2009259009A1 (es)
CA (1) CA2727326A1 (es)
CL (1) CL2010001422A1 (es)
CO (1) CO6280479A2 (es)
CR (1) CR11829A (es)
DO (1) DOP2010000365A (es)
EA (1) EA201071378A1 (es)
EC (1) ECSP10010666A (es)
IL (1) IL209791A0 (es)
MA (1) MA32462B1 (es)
MX (1) MX2010013698A (es)
NI (1) NI201000211A (es)
PE (1) PE20110055A1 (es)
SV (1) SV2010003756A (es)
TW (1) TW201002676A (es)
UY (1) UY31886A (es)
WO (1) WO2009150535A1 (es)
ZA (1) ZA201008871B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
NZ588623A (en) 2008-04-17 2012-11-30 Sanofi Aventis Use of a medicament containing dronedarone with food for preventing cardiovascular hospitalization
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
TWI508726B (zh) * 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
AU2014274638B2 (en) * 2009-12-21 2016-09-15 Gilead Sciences, Inc. Method of treating atrial fibrillation
EP2387997A1 (en) * 2010-05-18 2011-11-23 Sanofi Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients who developed permanent atrial fibrillation throughout the period the dronedarone is administered
TW201200131A (en) * 2010-05-13 2012-01-01 Sanofi Aventis Use of dronedarone for the preparation of a medicament for the prevention of cardiovacular hospitalizations or death or cardiovascular events in patients with premanent atrial fibrillation
EP2387996A1 (en) * 2010-05-17 2011-11-23 Sanofi Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
WO2012020377A1 (en) * 2010-08-11 2012-02-16 Sanofi Use of dronedarone for the preparation of a medicament for rhythm- and rate-controlling in patients with atrial fibrillation
US20130142849A1 (en) * 2010-08-17 2013-06-06 Lupin Limited Controlled release formulations of dronedarone
EP3326616B1 (en) * 2011-06-03 2021-07-28 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
EP2543362A1 (en) * 2011-07-07 2013-01-09 Sanofi Sustained release pharmaceutical oral solid dosage form of dronedarone or one of its pharmaceutically acceptable salts
EP2543361A1 (en) * 2011-07-07 2013-01-09 Sanofi Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts
EP2543363A1 (en) * 2011-07-07 2013-01-09 Sanofi Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts
FR2977495B1 (fr) * 2011-07-07 2014-03-07 Sanofi Sa Composition pharmaceutique et forme galenique solide a haute teneur en dronedarone et son procede de preparation
WO2013024411A1 (en) 2011-08-12 2013-02-21 Lupin Limited Co-milled formulation of dronedarone
CN112336445B (zh) * 2019-12-26 2021-11-26 上海微创电生理医疗科技股份有限公司 一种消融系统及其神经探测设备

Also Published As

Publication number Publication date
US20110166220A1 (en) 2011-07-07
SV2010003756A (es) 2011-03-15
NI201000211A (es) 2011-04-27
WO2009150535A1 (en) 2009-12-17
DOP2010000365A (es) 2011-01-15
IL209791A0 (en) 2011-02-28
EP2133074A1 (en) 2009-12-16
CL2010001422A1 (es) 2011-05-13
TW201002676A (en) 2010-01-16
CA2727326A1 (en) 2009-12-17
ZA201008871B (en) 2012-02-29
MA32462B1 (fr) 2011-07-03
MX2010013698A (es) 2011-02-23
AR072069A1 (es) 2010-08-04
ECSP10010666A (es) 2011-01-31
EP2300001A1 (en) 2011-03-30
EA201071378A1 (ru) 2011-06-30
AU2009259009A1 (en) 2009-12-17
UY31886A (es) 2010-01-29
CO6280479A2 (es) 2011-05-20
WO2009150535A8 (en) 2010-12-23
KR20110026422A (ko) 2011-03-15
JP2011522876A (ja) 2011-08-04
CN102056603A (zh) 2011-05-11
CR11829A (es) 2011-01-11

Similar Documents

Publication Publication Date Title
PE20110055A1 (es) Dronedarona para la prevencion de la fibrilacion auricular permanente
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
NO20091395L (no) Nye tiofenderivater
CU20080082A7 (es) Diarilureas para el tratamiento de hipertensión pulmonar
MX2009011002A (es) Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
HN2008000278A (es) Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion terapeutica
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
WO2009026657A8 (en) Flavonoid ppar agonists
NL1036050C (nl) Brandvertragende en brandwerende samenstelling.
ATE510822T1 (de) Kaliumkanalinhibitoren
ECSP10010471A (es) Agonistas nicotínicos alfa 7 y antipsicóticos
HN2006015130A (es) Asociacion entre la ferroquina y un derivado de artemisina para el tratamiento del paludismo
DOP2010000075A (es) Compuesto inhibidor de glicógeno fosforilasa y composicion farmaceutica del mismo
BR112012015084A2 (pt) composição farmacêutica de liberação lenta de iloperidone
MX2016007436A (es) Composiciones para el cuidado oral que comprenden carbonato de calcio y talco.
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
CL2010001421A1 (es) Uso de dronedarona en la preparacion de medicamentos utiles para la prevencion de fibrilacion o aleteo auricular persistentes.
BRPI0917554A2 (pt) agente de tratamento ou agente de prevenção para oesteoartrite
TR201101807T2 (tr) Rosuvastatin kalsiyumun farmasotik bileşimleri
ECSP10010552A (es) Asociacion de LA dronedarona con al menos un diuretico, su aplicacion en terapeutica
BRPI0816810A2 (pt) utilização de pelo menos um composto, e, composto.
GT200600408A (es) Nueva asociacion entre agomelatina y un inhibidor de recaptura de noradrenalina y composiciones farmaceuticas que la contienen
CL2007001794A1 (es) Compuestos derivados de 2-imidazolidinona, inhibidores del canal de potasio kv1.5; composicion farmaceutica que los comprende; y su uso para tratar o prevenir arritmias cardiacas. tromboembolia,apoplejia,insuficiencia cardiaca.
ECSP077208A (es) Inhibidores de los canales de potasio

Legal Events

Date Code Title Description
FD Application declared void or lapsed